Thompson Siegel & Walmsley LLC Puma Biotechnology, Inc. Transaction History
Thompson Siegel & Walmsley LLC
- $5.95 Billion
- Q1 2025
Shares
2 transactions
Others Institutions Holding PBYI
# of Institutions
115Shares Held
29.5MCall Options Held
32.7KPut Options Held
200-
Acorn Capital Advisors, LLC New York, NY3.94MShares$13.2 Million8.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.67MShares$12.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$11.9 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$6.59 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.83MShares$6.11 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $152M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...